Jaguar Health Inc., along with its family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., has announced the randomization of the first patient in a Phase 2 clinical trial evaluating crofelemer for pediatric patients with Microvillus Inclusion Disease (MVID). This double-blind, placebo-controlled study aims to assess the safety and efficacy of crofelemer, a novel antisecretory drug derived from the Croton lechleri tree, in reducing the need for total parenteral nutrition in patients with this ultrarare condition. Initial proof-of-concept results from an independent trial in Abu Dhabi indicated a 27% reduction in parenteral support. Results from the ongoing Phase 2 trial are expected in the second half of 2026. Jaguar Health is also exploring pathways for expedited regulatory approval in Europe and the U.S. through programs like PRIME and Breakthrough Therapy designation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.